Advanced anomaly analytics that enable detection and management of risks that may impact the outcome of clinical trials

Visit Website

---

Globally acknowledged as the company that invented and led the clinical data anomaly analytics revolution, CluePoints had invested a considerable resources on developing their Japanese business. However, it was not until the partnership with Matador came into full swing that the return on investment saw dramatic increases.

Matador leveraged their extensive software sales and Japan pharma experience to rapidly yield the material returns on investment which are now aligned with the size of the Japanese market. In the first year of the partnership sales improved over 100%, and Japan became an integral part of the success story of the global bus-dev team rather than an exception.

Japanese pharmaceutical companies now see CluePoints as a must-have technology to mitigate inherent risks that accompany clinical trials.